Follicular Lymphoma Ann Arbor lymphoma staging system | Therapeutic procedure Quantity | Persistent Disease | Recurrent disease | Refractory Disease
Item
diagnosis of grade 1-3 follicular lymphoma with persistent, relapsed, or refractory disease to at least one prior regimen.
boolean
C0024301 (UMLS CUI [1,1])
C0432516 (UMLS CUI [1,2])
C0087111 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
C2983415 (UMLS CUI [3])
C0277556 (UMLS CUI [4])
C1514815 (UMLS CUI [5])
Bortezomib Absent
Item
no prior bortezomib therapy.
boolean
C1176309 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
Informed Consent
Item
voluntary written informed consent.
boolean
C0021430 (UMLS CUI [1])
Postmenopausal state | Female Sterilization | Gender Contraceptive methods
Item
female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control.
boolean
C0232970 (UMLS CUI [1])
C0015787 (UMLS CUI [2])
C0079399 (UMLS CUI [3,1])
C0700589 (UMLS CUI [3,2])
Gender Contraceptive methods
Item
male subject agrees to use an acceptable method for contraception for the duration of the study therapy.
boolean
C0079399 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
Age
Item
18 years of age or older.
boolean
C0001779 (UMLS CUI [1])
Aspartate aminotransferase measurement | Alanine aminotransferase measurement | Serum total bilirubin measurement | Exclusion Measurement Secondary to Lymphoma
Item
aspartate aminotransferase (ast),alanine aminotransferase (alt), total bilirubin < 3 times the upper limit of normal unless documented by the treating physician to be secondary to underlying lymphoma.
boolean
C0201899 (UMLS CUI [1])
C0201836 (UMLS CUI [2])
C1278039 (UMLS CUI [3])
C2828389 (UMLS CUI [4,1])
C0242485 (UMLS CUI [4,2])
C0175668 (UMLS CUI [4,3])
C0024299 (UMLS CUI [4,4])
ECOG performance status
Item
eastern cooperative oncology group (ecog) performance status 0-2.
boolean
C1520224 (UMLS CUI [1])
Platelet Count measurement | Exclusion Platelet count Due to Disease
Item
platelet count of < 50,000 within 14 days before enrollment unless documented by the treating physician to be due to the disease.
boolean
C0032181 (UMLS CUI [1])
C2828389 (UMLS CUI [2,1])
C1287267 (UMLS CUI [2,2])
C0678226 (UMLS CUI [2,3])
C0012634 (UMLS CUI [2,4])
Absolute neutrophil count | Exclusion ANC Due to Disease
Item
absolute neutrophil count of < 1000 within 14 days before enrollment unless documented by the treating physician to be due to disease.
boolean
C0948762 (UMLS CUI [1])
C2828389 (UMLS CUI [2,1])
C0948762 (UMLS CUI [2,2])
C0678226 (UMLS CUI [2,3])
C0012634 (UMLS CUI [2,4])
Estimation of creatinine clearance by Cockcroft-Gault formula | Creatinine clearance measurement
Item
estimated or measured creatinine clearance of less than 30 ml/min within 14 days before enrollment.
boolean
C2711451 (UMLS CUI [1])
C0373595 (UMLS CUI [2])
Peripheral Neuropathy CTCAE Grades
Item
≥grade 2 peripheral neuropathy within 14 days before enrollment.
boolean
C0031117 (UMLS CUI [1,1])
C1516728 (UMLS CUI [1,2])
Myocardial Infarction | Heart failure New York Heart Association Classification | Angina Pectoris Uncontrolled | Ventricular arrhythmia Uncontrolled Severe | Ischemia Electrocardiography
Item
myocardial infarction within 6 months prior to enrollment or has new york hospital association (nyha) class iii or iv heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia.
boolean
C0027051 (UMLS CUI [1])
C0018801 (UMLS CUI [2,1])
C1275491 (UMLS CUI [2,2])
C0002962 (UMLS CUI [3,1])
C0205318 (UMLS CUI [3,2])
C0085612 (UMLS CUI [4,1])
C0205318 (UMLS CUI [4,2])
C0205082 (UMLS CUI [4,3])
C0022116 (UMLS CUI [5,1])
C1623258 (UMLS CUI [5,2])
Hypersensitivity Boron | Mannitol allergy | Hypersensitivity Investigational New Drugs
Item
patient has hypersensitivity to boron, mannitol or any drug included in the current protocol.
boolean
C0020517 (UMLS CUI [1,1])
C0006030 (UMLS CUI [1,2])
C0571922 (UMLS CUI [2])
C0020517 (UMLS CUI [3,1])
C0013230 (UMLS CUI [3,2])
Pregnancy | Breast Feeding
Item
female subject is pregnant or lactating.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Investigational New Drugs
Item
received other investigational drugs for this disease within 14 days of enrollment
boolean
C0013230 (UMLS CUI [1])
Illness Serious Interferes with Study Subject Participation Status | Serious mental illness Interferes with Study Subject Participation Status
Item
serious medical or psychiatric illness likely to interfere with participation in this clinical study.
boolean
C0221423 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C0521102 (UMLS CUI [1,3])
C2348568 (UMLS CUI [1,4])
C3841614 (UMLS CUI [2,1])
C0521102 (UMLS CUI [2,2])
C2348568 (UMLS CUI [2,3])
HIV Seropositivity
Item
known hiv+ status.
boolean
C0019699 (UMLS CUI [1])
Cardiac ejection fraction Echocardiography | Cardiac ejection fraction Multiple gated acquisition scanning | Cardiac ejection fraction MRI of Heart
Item
cardiac ejection fraction less than 35% at study entry measured by echocardiogram, multigated acquisition (muga) or cardiac mri.
boolean
C0232174 (UMLS CUI [1,1])
C0013516 (UMLS CUI [1,2])
C0232174 (UMLS CUI [2,1])
C0521317 (UMLS CUI [2,2])
C0232174 (UMLS CUI [3,1])
C0412692 (UMLS CUI [3,2])